Table 2.
Association of SNPs with NAFLD characteristics*
| SNP | rs780094 | rs2228603 | rs1213785 | rs4240624 | rs738409 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Effect allele | T | T | C | A | G | ||||||||
| Other allele | C | C | T | G | C | ||||||||
| Effect allele Frequency | 40.9 | 7.4 | 73.5 | 8.3 | 22.0 | ||||||||
| Nearest gene | GCKR | NCAN | LYPLAL1 | PPP1R3B | PNPLA3 | ||||||||
| Genotypes | TT N=186 |
CT N=522 |
CC N=384 |
−T N=155 |
CC N=928 |
CC N=696 |
CT N=325 |
TT N=39 |
AA N=883 |
− G N=172 |
GG N=54 |
GC N=370 |
CC N=664 |
| Steatosis§ (mean) | 1.16 | 1.07 | 1.02 | 1.22 | 1.03 | 1.07 | 1.06 | 1.11 | 1.08 | 1.02 | 1.63 | 1.16 | 0.96 |
| SE | 0.07 | 0.04 | 0.05 | 0.07 | 0.03 | 0.04 | 0.05 | 0.15 | 0.03 | 0.07 | 0.13 | 0.05 | 0.03 |
| p-value | 0.19 | 0.03 | 0.86 | 0.49 | 4.80E-08 | ||||||||
| Lobular inflammation¥ (% > grade 0) | 34.4 | 30.9 | 31.1 | 39.7 | 30.1 | 31.4 | 32.2 | 32.4 | 31.4 | 32.7 | 32.7 | 34.8 | 29.6 |
| p-value | 0.68 | 0.02 | 0.98 | 0.68 | 0.11 | ||||||||
| Hepatocyte Ballooning¥ (% > grade 0) | 23.4 | 29.1 | 21.6 | 32.6 | 23.7 | 24.2 | 28.0 | 23.8 | 24.9 | 27.6 | 31.4 | 31.3 | 21.5 |
| p-value | 0.48 | 0.06 | 0.49 | 0.48 | 0.006 | ||||||||
| Perivenular fibrosis¥ (% > grade 0) | 20.0 | 18.8 | 18.8 | 27.8 | 17.2 | 19.2 | 18.0 | 21.6 | 19.1 | 17.3 | 21.2 | 22.0 | 17.1 |
| p-value | 0.98 | 0.002 | 0.74 | 0.65 | 0.06 | ||||||||
| Cirrhosis¥ (% > grade 0) | 2.8 | 2.5 | 1.6 | 4.0 | 2.1 | 2.5 | 1.9 | 2.7 | 2.0 | 4.2 | 1.9 | 3.3 | 1.7 |
| p-value | 0.47 | 0.21 | 0.61 | 0.07 | 0.21 | ||||||||
*
Age-, sex-, and lipid lowering medication-adjusted mean and standard error are presented for each genotype group.
§
Steatosis was examined histologically and graded in severity from 0 (no steatosis) to 3 (severe steatosis).
¥
Dichotomized grade 0 vs. >0 for inflammation, ballooning, fibrosis and cirrhosis.